Latest News

Postvaccination febrile seizures are no more severe than other febrile seizures


 

FROM PEDIATRICS

The severity and duration of vaccine-proximate febrile seizures (VP-FSs) are no worse than non–vaccine proximate febrile seizures (NVP-FSs), according to a study in Pediatrics.

Toddler is held by mother while being vaccinated by doctor. KatarzynaBialasiewicz/Thinkstock

Lucy Deng, MBBS, of the University of Sydney and her colleagues investigated 1,022 index febrile seizures in children aged 6 years or less, of which 6% (n = 67) were VP-FSs and 94% (n = 955) were NVP-FSs. Both univariate and multivariate analyses showed no increased risk of severe seizure associated with VP-FSs, compared with NVP-FS. Most of the febrile seizures of either type were brief (15 minutes or less) and had a length of stay of 1 day or less; there also were no differences in 24-hour recurrence. The most common symptom was respiratory, and the rates were similar in each group (62.7% with VP-FS vs. 62.8% with NVP-FS). In keeping with a known 100% increased risk associated with measles vaccination, 84% of VP-FSs were associated with measles-containing vaccines. The majority of the remaining VP-FSs occurred after combination vaccines.

One limitation is that, because these cases were documented in sentinel tertiary pediatric hospitals, the case ascertainment may not be representative. Also, the small proportion of VP-FSs and limited cohort size means the study may not have been powered to detect true differences in prolonged seizures between the groups, Dr. Deng and her colleagues wrote.

“This study confirms that VP-FSs are clinically not any different from NVP-FSs and should be managed the same way,” the researchers concluded.

The authors reported no relevant financial disclosures, although Dr. Deng is supported by the University of Sydney Training Program scholarship, and two other study authors are supported by Australian National Health and Medical Research Council Career Development Fellowships. The study was funded by a grant from the Australian Government Department of Health and the National Health and Medical Research Council.

SOURCE: Deng L et al. Pediatrics. 2019 Apr 19. doi: 10.1542/peds.2018-2120.

Recommended Reading

MenB vaccine receives breakthrough therapy designation for children aged 1-9 years
MDedge Neurology
Analysis finds inconsistent uptake of meningococcal B vaccines
MDedge Neurology
MDedge Daily News: Do HPV vaccines really cut cancer risk?
MDedge Neurology
Vaccine-related febrile seizures have zero developmental impact
MDedge Neurology
French warn of upsurge in pneumococcal meningitis
MDedge Neurology
Aspirin and Omega-3 fatty acids fail
MDedge Neurology
Cerebral small vessel and cognitive impairment
MDedge Neurology
Cyberbullied by anti-vaxxers: Monique Tello Part I
MDedge Neurology
Conservatism spreads in prostate cancer
MDedge Neurology
Vaccination and antiviral treatment do not affect stroke risk following shingles
MDedge Neurology